Dianthus Therapeutics develops monoclonal antibody therapies aimed at severe autoimmune and inflammatory diseases. Its lead candidate, claseprubart (DNTH103), is engineered for high selectivity against the active C1s complement protein, extended half-life, and less frequent subcutaneous dosing. The pipeline also includes DNTH212, a bifunctional fusion protein designed to dampen Type I interferon signaling and B-cell activity. The company is clinical-stage and focused on complement and related immune pathways rather than marketed products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1.2 | — | -29.5 | — |
| Q2 2025 | 0.2 | — | -31.6 | — |
| Q3 2025 | 0.4 | — | -36.8 | — |
| Q4 2025 | 0.3 | — | -64.4 | — |
| Q1 2026 | 0.5 | -60.2% | -40.8 | — |
| Q2 2026 | 0.8 | 294.3% | -50.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Rigetti Computing, Inc. (RGTI), Texas Capital Bancshares, Inc. (TCBI), TORM plc (TRMD), WSFS Financial Corporation (WSFS), BRP Inc. (DOO), CVB Financial Corp. (CVBF)